GlassScriptPhysician profile
Adam C Craner
NPI 1952326357
$5,652.75
in general payments reported to CMS, 2019-2025
45 companies · $920 in 2025
The $920 reported for 2025 was more than what 85% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $827 · 2022: $710 · 2023: $1,514 · 2024: $1,682 · 2025: $920.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,036 · Education: $79.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,035.98 |
| Education | $79.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,036.01 | 2021-2025 | |
| Amgen INC. | $929.52 | 2021-2024 | Evenity, Prolia, Repatha |
| Astellas Pharma US INC | $583.59 | 2021-2025 | Veozah, Myrbetriq |
| Novo Nordisk INC | $443.34 | 2021-2025 | Wegovy, Ozempic, Rybelsus |
| Lilly USA, LLC | $319.12 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Amarin Pharma, INC. | $286.25 | 2021-2022 | |
| Otsuka America Pharmaceutical, INC. | $206.67 | 2023-2025 | Rexulti |
| Phathom Pharmaceuticals, INC. | $152.44 | 2024-2025 | Voquezna |
| Janssen Pharmaceuticals, INC | $135.10 | 2021-2024 | Spravato, Xarelto |
| Pfizer INC. | $131.45 | 2021-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $114.40 | 2025 | Caplyta |
| Astrazeneca Pharmaceuticals LP | $111.43 | 2021-2025 | Farxiga, Breztri |
| Abbott Laboratories | $92.10 | 2022-2024 | Freestyle Libre 2, Freestyle Libre 3 |
| Eisai INC. | $88.93 | 2021 | |
| Exact Sciences Corporation | $84.61 | 2024-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
Show all 45 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Adam Craner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.